Shattuck Labs (STTK) Non-Current Deffered Revenue (2019 - 2021)
Shattuck Labs (STTK) posted quarterly Non-Current Deffered Revenue of $2.2 million for Q4 2021, down 89.61% year-over-year from $21.3 million in Q4 2020, and down 91.89% quarter-over-quarter from $27.3 million in Q3 2021.
Analysis
Shattuck Labs (STTK) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends
Shattuck Labs (STTK) has reported Non-Current Deffered Revenue for 3 consecutive years, with $2.2 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue fell 89.61% year-over-year to $2.2 million; the TTM figure through Dec 2021 stood at $2.2 million (down 89.61% YoY), while the FY2021 annual figure was $2.2 million, down 89.61% from the prior year.
- Non-Current Deffered Revenue fell to $2.2 million in Q4 2021 per STTK's latest filing, from $27.3 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $29.2 million in Q2 2021 and bottomed at $898000.0 in Q4 2019.
- Historically, Non-Current Deffered Revenue has averaged $12.0 million across 3 years, with a median of $2.2 million in 2021.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 2894.18% in 2021 and fell as far as 89.61% in 2021.
- Shattuck Labs' Non-Current Deffered Revenue stood at $898000.0 in 2019, then soared by 2272.61% to $21.3 million in 2020, then tumbled by 89.61% to $2.2 million in 2021.
- Business Quant data shows STTK's Non-Current Deffered Revenue at $2.2 million in Q4 2021, $27.3 million in Q3 2021, and $29.2 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 27.28 Mn |
| Jun 30, 2021 | 29.22 Mn |
| Mar 31, 2021 | 18.09 Mn |
| Dec 31, 2020 | 21.31 Mn |
| Sep 30, 2020 | 19.72 Mn |
| Dec 31, 2019 | 9.57 Mn |